Evonik Plans Isophorone Capacity Expansion
“Isophorone chemistry is a core business for Evonik,” said Klaus Engel, chairman of the Executive Board. “The market for isophorone and its derivatives is growing steadily and proved to be robust even during the economic crisis. That’s why we want to sustainably strengthen our market and technological leadership by capacity expansion.”
For additional details, visit www.evonik.com.